Merck Consumer Care’s Oxytrol for Women brings women with overactive bladder concerns to the self-care aisle for the first time. And this is good, because, on average, women who suffer from OAB wait more than three years before seeking care. With an OTC solution available, more women probably will address their condition sooner. With 20 million OAB sufferers, sales of Oxytrol are projected to reach as high as $50 million.
(For the complete category review, including data, click here.)